| RS2143823499 |
GAA
|
Health Risk |
Pathogenic |
— |
| RS2143824066 |
LOXHD1
|
Health Risk |
Pathogenic/Likely pathogenic |
Autosomal recessive nonsyndromic hearing loss 77, Autosomal recessive nonsyndromic hearing loss 77 |
| RS2143825870 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143826963 |
GAA
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease, type II |
| RS2143827149 |
GAA
|
Health Risk |
Likely pathogenic |
— |
| RS2143827215 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2143827701 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143829023 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143829478 |
GAA
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease, type II |
| RS2143829649 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143833579 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143834462 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143834640 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143834983 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143838681 |
MKS1
|
Health Risk |
Pathogenic |
Joubert syndrome, Meckel-Gruber syndrome |
| RS2143842283 |
PIEZO2;MIR6788
|
Health Risk |
Pathogenic/Likely pathogenic |
Arthrogryposis, distal |
| RS2143843115 |
PIEZO2
|
Health Risk |
Pathogenic |
— |
| RS2143845687 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2143845939 |
FSCN2
|
Health Risk |
Likely pathogenic |
Retinal dystrophy, Retinal dystrophy |
| RS2143846283 |
GAA
|
Health Risk |
Conflicting classifications of pathogenicity |
Glycogen storage disease, type II |
| RS2143847172 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143848897 |
GAA
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease, type II |
| RS2143849151 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143849443 |
STRADA
|
Health Risk |
Pathogenic |
Polyhydramnios, megalencephaly |
| RS2143849751 |
GAA
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease, type II |
| RS2143849978 |
RAD51C
|
Health Risk |
Pathogenic |
Breast-ovarian cancer, familial |
| RS2143850723 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Fanconi anemia complementation group O |
| RS2143852568 |
RAD51C
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group O, Fanconi anemia complementation group O |
| RS2143852733 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143853617 |
RAD51C
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group O, Hereditary cancer-predisposing syndrome |
| RS2143853690 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143853726 |
RAD51C
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Gastric cancer |
| RS2143853790 |
RAD51C
|
Health Risk |
Likely pathogenic |
Breast-ovarian cancer, familial |
| RS2143853890 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2143854537 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143854659 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143854758 |
RAD51C
|
Health Risk |
Pathogenic/Likely pathogenic |
Breast-ovarian cancer, familial |
| RS2143854783 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Fanconi anemia complementation group O, Hereditary cancer-predisposing syndrome |
| RS2143856709 |
TBX4
|
Health Risk |
Likely pathogenic |
Pulmonary hypertension, primary |
| RS2143856758 |
TBX4
|
Health Risk |
Conflicting classifications of pathogenicity |
Pulmonary hypertension, primary |
| RS2143857127 |
TBX4
|
Health Risk |
Likely pathogenic |
Pulmonary hypertension, primary |
| RS2143857207 |
GAA
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease, type II |
| RS2143858151 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143858305 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143860891 |
UNC13D
|
Health Risk |
Likely pathogenic |
Autoinflammatory syndrome, Autoinflammatory syndrome |
| RS2143860927 |
TBX4
|
Health Risk |
Pathogenic |
Coxopodopatellar syndrome, Coxopodopatellar syndrome |
| RS2143861174 |
TBX4
|
Health Risk |
Likely pathogenic |
Pulmonary hypertension, primary |
| RS2143861305 |
UNC13D
|
Health Risk |
Likely pathogenic |
Familial hemophagocytic lymphohistiocytosis 3, Familial hemophagocytic lymphohistiocytosis 3 |
| RS2143862827 |
TBX4
|
Health Risk |
Pathogenic |
— |
| RS2143865621 |
UNC13D
|
Health Risk |
Pathogenic |
Familial hemophagocytic lymphohistiocytosis 3, Familial hemophagocytic lymphohistiocytosis 3 |
| RS2143865725 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143866086 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2143866239 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143866303 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2143866321 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143866454 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2143866789 |
METTL23
|
Health Risk |
Likely pathogenic |
Intellectual disability, autosomal recessive 44 |
| RS2143867385 |
METTL23
|
Health Risk |
Pathogenic |
— |
| RS2143871845 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143872026 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143872061 |
TBX4
|
Health Risk |
Likely pathogenic |
Pulmonary hypertension, primary |
| RS2143872212 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2143872219 |
GAA
|
Health Risk |
Conflicting classifications of pathogenicity |
Glycogen storage disease, type II |
| RS2143872349 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143872369 |
PYCR1
|
Health Risk |
Likely pathogenic |
Autosomal recessive cutis laxa type 2B, Autosomal recessive cutis laxa type 2B |
| RS2143872679 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143872904 |
NF1
|
Health Risk |
Pathogenic |
Cardiovascular phenotype, Hereditary cancer-predisposing syndrome |
| RS2143873095 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143873205 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143873387 |
NF1
|
Health Risk |
Pathogenic |
NF1-related disorder, NF1-related disorder |
| RS2143873403 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143873634 |
NF1
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Cardiovascular phenotype |
| RS2143873673 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143873710 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143873786 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143873811 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis-Noonan syndrome, Neurofibromatosis-Noonan syndrome |
| RS2143873866 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143873917 |
IKZF3
|
Health Risk |
Pathogenic |
Immunodeficiency 84, Immunodeficiency 84 |
| RS2143874087 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143874110 |
NF1
|
Health Risk |
Pathogenic |
— |
| RS2143874124 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143874127 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143874147 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143874154 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143874232 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143874287 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2143874352 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2143874398 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143874573 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143874754 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2143875175 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2143875243 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2143876026 |
UNC13D
|
Health Risk |
Pathogenic |
Familial hemophagocytic lymphohistiocytosis 3, Familial hemophagocytic lymphohistiocytosis 3 |
| RS2143877155 |
UNC13D
|
Health Risk |
Conflicting classifications of pathogenicity |
Autoinflammatory syndrome, Familial hemophagocytic lymphohistiocytosis 3 |
| RS2143878241 |
UNC13D
|
Health Risk |
Likely pathogenic |
Autoinflammatory syndrome, Autoinflammatory syndrome |
| RS2143878420 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143878590 |
NF1
|
Health Risk |
Pathogenic |
— |
| RS2143878810 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143878832 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143878939 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |